Akebia Therapeutics (AKBA) Short Interest Ratio & Short Volume $1.87 +0.03 (+1.63%) (As of 12/17/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Akebia Therapeutics Short Interest DataAkebia Therapeutics (AKBA) has a short interest of 11.56 million shares. This marks a -3.34% decrease in short interest from the previous month. The short interest ratio (days to cover) is 6.2, indicating that it would take 6.2 days of the average trading volume of 3.02 million shares to cover all short positions.Current Short Interest11,560,000 sharesPrevious Short Interest11,960,000 sharesChange Vs. Previous Month-3.34%Dollar Volume Sold Short$23.81 millionShort Interest Ratio6.2 Days to CoverLast Record DateNovember 30, 2024Outstanding Shares218,181,000 sharesPercentage of Shares Shorted5.30%Today's Trading Volume1,520,469 sharesAverage Trading Volume3,019,370 sharesToday's Volume Vs. Average50% Short Selling Akebia Therapeutics? Sign up to receive the latest short interest report for Akebia Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartAKBA Short Interest Over TimeAKBA Days to Cover Over TimeAKBA Percentage of Float Shorted Over Time Ad Brownstone ResearchDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. Akebia Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 11/30/202411,560,000 shares $23.81 million -3.3%N/A6.2 $2.06 11/15/202411,960,000 shares $21.41 million -19.4%N/A6.5 $1.79 10/31/202414,840,000 shares $24.63 million -16.1%N/A8.1 $1.66 10/15/202417,680,000 shares $23.16 million -6.0%N/A10.6 $1.31 9/30/202418,800,000 shares $24.82 million -1.4%N/A10.1 $1.32 9/15/202419,060,000 shares $27.83 million -0.1%N/A7.2 $1.46 Get the Latest News and Ratings for AKBA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/202419,070,000 shares $29.56 million +0.6%N/A6.9 $1.55 8/15/202418,950,000 shares $27.29 million +5.9%N/A6.6 $1.44 7/31/202417,890,000 shares $24.69 million -4.1%N/A5.9 $1.38 7/15/202418,660,000 shares $24.44 million +42.3%N/A5.8 $1.31 6/30/202413,110,000 shares $13.37 million +6.6%N/A4 $1.02 6/15/202412,300,000 shares $13.16 million -6.5%N/A2.7 $1.07 5/31/202413,160,000 shares $14.74 million +12.5%N/A2.7 $1.12 5/15/202411,700,000 shares $13.81 million -1.4%N/A2.3 $1.18 4/30/202411,860,000 shares $14.94 million -13.4%N/A2.4 $1.26 4/15/202413,690,000 shares $19.03 million +2.2%N/A2.9 $1.39 3/31/202413,400,000 shares $24.52 million +32.3%N/A3 $1.83 3/15/202410,130,000 shares $17.22 million +24.9%N/A3.4 $1.70 2/29/20248,110,000 shares $12.81 million +1.4%N/A4 $1.58 2/15/20248,000,000 shares $11.76 million -8.9%N/A4.5 $1.47 1/31/20248,780,000 shares $14.75 million +12.1%N/A5.4 $1.68 1/15/20247,830,000 shares $12.14 million -0.5%N/A5 $1.55 12/31/20237,870,000 shares $9.76 million +7.4%N/A5.3 $1.24 12/15/20237,330,000 shares $8.43 million -18.7%N/A5.5 $1.15 11/30/20239,010,000 shares $9.55 million -8.8%N/A6.9 $1.06 11/15/20239,880,000 shares $9.88 million -4.3%N/A6.8 $1.00 10/31/202310,320,000 shares $9.08 million +33.2%N/A6.8 $0.88 10/15/20237,750,000 shares $7.03 million +6.5%N/A4.5 $0.91 9/30/20237,280,000 shares $8.30 million +0.7%N/A4.4 $1.14 9/15/20237,230,000 shares $9.11 million +24.4%N/A4.1 $1.26 8/31/20235,810,000 shares $8.08 million -14.1%N/A3.1 $1.39 8/15/20236,760,000 shares $8.86 million +10.3%N/A3.2 $1.31 7/31/20236,130,000 shares $10.24 million +13.7%N/A2.8 $1.67 7/15/20235,390,000 shares $5.71 million +11.4%N/A2.9 $1.06 6/30/20234,840,000 shares $4.43 million +11.3%N/A2.7 $0.92 6/15/20234,350,000 shares $4.96 million -15.5%N/A2.5 $1.14 5/31/20235,150,000 shares $5.36 million +26.5%N/A3 $1.04 5/15/20234,070,000 shares $4.44 million -9.6%N/A2.4 $1.09 4/30/20234,500,000 shares $4.09 million -20.8%N/A2.4 $0.91 4/15/20235,680,000 shares $3.57 million +0.4%N/A2.9 $0.63Do this Before Elon’s Reveal on January 22nd (Ad)Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. 3/31/20235,660,000 shares $3.17 million -15.3%N/A2.8 $0.56 3/15/20236,680,000 shares $4.49 million -20.3%N/A3 $0.67 2/28/20238,380,000 shares $7.06 million +82.6%N/A3.5 $0.84 2/15/20234,590,000 shares $4.07 million +38.3%N/A2 $0.89 1/31/20233,320,000 shares $2.09 million -28.1%N/A1.7 $0.63 1/15/20234,620,000 shares $3.21 million -0.9%N/A2.7 $0.70 12/30/20224,660,000 shares $2.69 million -0.4%N/A2.7 $0.58 12/15/20224,680,000 shares $2.12 million -2.9%N/A3.1 $0.45 11/30/20224,820,000 shares $1.30 million -12.5%N/A3.4 $0.27 11/15/20225,510,000 shares $1.41 million -6.9%N/A3.8 $0.26 10/31/20225,920,000 shares $1.51 million -5.9%N/A3.4 $0.25 10/15/20226,290,000 shares $1.82 million -13.4%N/A2.7 $0.29 9/30/20227,260,000 shares $2.30 million -5.8%N/A2.6 $0.32 9/15/20227,710,000 shares $2.85 million -3.5%N/A1.1 $0.37 8/31/20227,990,000 shares $2.91 million -14.5%N/A1 $0.36 8/15/20229,340,000 shares $3.87 million -18.5%N/A1 $0.41 7/31/202211,460,000 shares $4.48 million +1.4%N/A1.1 $0.39 7/15/202211,300,000 shares $4.77 million +19.5%N/A1 $0.42 6/30/20229,460,000 shares $3.34 million -39.6%N/A0.7 $0.35 6/15/202215,660,000 shares $5.53 million -11.9%N/A1.2 $0.35 5/31/202217,780,000 shares $6.58 million -8.1%N/A1.5 $0.37 5/15/202219,340,000 shares $8.68 million +1.2%N/A1.8 $0.45 4/30/202219,120,000 shares $7.94 million +12.3%N/A1.9 $0.42 4/15/202217,020,000 shares $9.16 million -20.5%N/A1.9 $0.54 3/31/202221,410,000 shares $15.37 million +44.1%N/A3 $0.72 3/15/202214,860,000 shares $34.18 million +12.9%N/A3.8 $2.30 2/28/202213,160,000 shares $28.43 million +7.6%N/A3.5 $2.16 2/15/202212,230,000 shares $22.38 million +9.0%N/A3.6 $1.83 1/31/202211,220,000 shares $22.33 million +9.9%N/A3.5 $1.99 1/15/202210,210,000 shares $22.46 million -10.0%N/A3.4 $2.20 12/31/202111,350,000 shares $25.65 million -4.2%N/A4.1 $2.26 12/15/202111,850,000 shares $29.03 million +4.1%N/A4.6 $2.45 11/30/202111,380,000 shares $30.84 million +10.3%N/A5.5 $2.71 11/15/202110,320,000 shares $29.62 million -11.2%N/A5.1 $2.87 10/29/202111,620,000 shares $33.35 million +1.9%N/A5.8 $2.87 10/15/202111,400,000 shares $32.49 million -10.2%N/A5.3 $2.85 9/30/202112,690,000 shares $36.55 million +1.5%N/A4.1 $2.88 9/15/202112,500,000 shares $34.75 million -6.6%N/A3.9 $2.78 8/31/202113,380,000 shares $39.34 million +2.8%N/A3.7 $2.94 8/13/202113,010,000 shares $32.79 million -6.9%N/A3.4 $2.52 7/30/202113,980,000 shares $34.53 million -11.0%N/A3.6 $2.47 7/15/202115,700,000 shares $52.12 million +2.9%10.3%4.1 $3.32 6/30/202115,260,000 shares $57.84 million -2.2%10.0%4.6 $3.79 6/15/202115,610,000 shares $54.95 million -3.0%10.2%4.5 $3.52 5/28/202116,090,000 shares $56.48 million -11.7%10.6%4.5 $3.51 5/14/202118,220,000 shares $60.67 million -0.3%N/A4.3 $3.33 4/30/202118,280,000 shares $59.41 million -7.2%N/A3.6 $3.25 4/15/202119,690,000 shares $61.33 million -7.6%N/A3.3 $3.12 3/31/202121,300,000 shares $65.92 million -15.2%N/A3.3 $3.10 3/15/202125,130,000 shares $90.72 million -1.5%N/A3.7 $3.61Do this Before Elon’s Reveal on January 22nd (Ad)Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. 2/26/202125,500,000 shares $88.49 million -3.2%N/A3.7 $3.47 2/12/202126,350,000 shares $125.69 million -4.0%N/A4 $4.77 1/29/202127,450,000 shares $94.02 million -4.8%N/A4.4 $3.43 1/15/202128,820,000 shares $91.36 million +0.5%N/A4.5 $3.17 12/31/202028,680,000 shares $85.75 million +20.9%N/A4.4 $2.99 12/15/202023,730,000 shares $75.46 million +0.8%N/A3.7 $3.18 11/30/202023,540,000 shares $79.80 million -6.2%N/A3.3 $3.39 11/15/202025,100,000 shares $63.75 million -6.1%N/A3 $2.54 10/30/202026,730,000 shares $60.68 million +7.7%N/A3.4 $2.27 10/15/202024,830,000 shares $88.89 million +12.0%N/A3.7 $3.58 9/30/202022,170,000 shares $55.65 million +141.8%N/A4.3 $2.51 9/15/20209,170,000 shares $24.21 million +12.4%N/A2 $2.64 8/31/20208,160,000 shares $84.95 million -10.0%N/A2.4 $10.41 8/14/20209,070,000 shares $95.51 million -5.2%N/A6.9 $10.53 7/31/20209,570,000 shares $106.90 million -1.8%N/A6.5 $11.17 7/15/20209,740,000 shares $120.29 million +1.0%N/A5.6 $12.35 6/30/20209,640,000 shares $122.43 million +61.5%N/A5.5 $12.70 6/15/20205,970,000 shares $72.42 million +18.5%N/A3.7 $12.13 5/29/20205,040,000 shares $58.67 million -21.3%N/A3 $11.64 5/15/20206,400,000 shares $79.49 million -16.0%N/A3.7 $12.42 4/30/20207,620,000 shares $61.72 million +3.8%N/A4.6 $8.10 4/15/20207,340,000 shares $53.36 million +8.3%N/A5.3 $7.27 3/31/20206,780,000 shares $52.27 million -6.5%5.8%4.4 $7.71 3/13/20207,251,800 shares $50.76 million -2.4%7.0%4.2 $7.00 2/28/20207,430,000 shares $46.29 million -5.6%7.2%5.3 $6.23 2/14/20207,870,000 shares $58.47 million -9.5%7.3%5 $7.43 1/31/20208,700,000 shares $76.82 million -6.9%8.2%5.4 $8.83 1/15/20209,340,000 shares $84.71 million -5.1%8.8%6.3 $9.07 12/31/20199,840,000 shares $78.03 million -4.4%9.3%7.6 $7.93 AKBA Short Interest - Frequently Asked Questions What is Akebia Therapeutics' current short interest? Short interest is the volume of Akebia Therapeutics shares that have been sold short but have not yet been closed out or covered. As of November 30th, investors have sold 11,560,000 shares of AKBA short. Learn More on Akebia Therapeutics' current short interest. What is a good short interest ratio for Akebia Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. AKBA shares currently have a short interest ratio of 6.0. Learn More on Akebia Therapeutics's short interest ratio. Is Akebia Therapeutics' short interest increasing or decreasing? Akebia Therapeutics saw a drop in short interest in the month of November. As of November 30th, there was short interest totaling 11,560,000 shares, a drop of 3.3% from the previous total of 11,960,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Akebia Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Akebia Therapeutics: Galapagos NV (2.68%), Xencor, Inc. (6.37%), Arvinas, Inc. (13.13%), NewAmsterdam Pharma (6.04%), Evotec SE (0.14%), Arcus Biosciences, Inc. (16.69%), Immunocore Holdings plc (14.78%), Kiniksa Pharmaceuticals, Ltd. (5.57%), Intellia Therapeutics, Inc. (18.57%), Ocular Therapeutix, Inc. (6.78%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.70 billion), Charter Communications, Inc. ($4.55 billion), Spotify Technology S.A. ($3.84 billion), Royal Caribbean Cruises Ltd. ($3.07 billion), International Paper ($3.00 billion), Coinbase Global, Inc. ($2.93 billion), Cencora, Inc. ($2.54 billion), Paychex, Inc. ($2.53 billion), SoFi Technologies, Inc. ($2.24 billion), and Reddit, Inc. ($2.00 billion). View all of the most shorted stocks. What does it mean to sell short Akebia Therapeutics stock? Short selling AKBA is an investing strategy that aims to generate trading profit from Akebia Therapeutics as its price is falling. AKBA shares are trading up $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Akebia Therapeutics? A short squeeze for Akebia Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of AKBA, which in turn drives the price of the stock up even further. How often is Akebia Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AKBA, twice per month. The most recent reporting period available is November, 30 2024. More Short Interest Resources from MarketBeat Related Companies ARQT Short Interest Data NRIX Short Interest Data RCUS Short Interest Data KNSA Short Interest Data IMCR Short Interest Data OCUL Short Interest Data MESO Short Interest Data TVTX Short Interest Data NTLA Short Interest Data PRAX Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:AKBA) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AKBA Stock Alerts